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Abstract
Background. Non-motor features of Parkinson’s disease (PD) and dementia with Lewy bodies
(DLB), such as auditory hallucinations (AH), contribute to disease burden but are not well
understood.
Methods. Systematic review and random-effects meta-analyses of studies reporting AH asso-
ciated with PD or DLB. Prevalence of visual hallucinations (VH) in identified studies meeting
eligibility criteria were included in meta-analyses, facilitating comparison with AH. Synthesis
of qualitative descriptions of AH was performed. PubMed, Web of Science and Scopus data-
bases were searched for primary journal articles, written in English, published from 1970 to
2017. Studies reporting AH prevalence in PD or DLB were screened using PRISMA methods.
Results. Searches identified 4542 unique studies for consideration, of which, 26 met inclusion
criteria. AH pooled prevalence in PD was estimated to be 8.9% [95% confidence interval (CI)
5.3–14.5], while in DLB was estimated to be 30.8% (±23.4 to 39.3). Verbal hallucinations, per-
ceived as originating outside the head, were the most common form of AH. Non-verbal AH
were also common while musical AH were rare. VH were more prevalent, with an estimated
pooled prevalence in PD of 28.2% (±19.1 to 39.5), while in DLB they were estimated to be
61.8% (±49.1 to 73.0). Meta-regression determined that the use of validated methodologies
to identify hallucinations produced higher prevalence estimates.
Conclusions. AH and VH present in a substantial proportion of PD and DLB cases, with VH
reported more frequently in both conditions. Both AH and VH are more prevalent in DLB
than PD. There is a need for standardised use of validated methods to detect and monitor
hallucinations.
Introduction
Parkinson’s disease (PD) and dementia with Lewy bodies (DLB) are neurodegenerative dis-
eases associated with α-synuclein dysfunction. Estimates suggest PD prevalence is 1% in peo-
ple over 60 (De Lau and Breteler, 2006), while DLB has a prevalence of 0.4% in people over 65
(Vann Jones and O’Brien, 2014). Both conditions are characterised by motor dysfunction but
non-motor features contribute extensively to their presentation and disease burden.
Hallucinations, spontaneous aberrant perceptions, occur in a significant proportion of
cases (Diederich et al., 2009). Hallucinations can be induced by medications such as anticho-
linergics (Celesia and Wanamaker, 1972), dopamine agonists (Baker et al., 2009) and a range
of medications modulating diverse neurochemical pathways (Porteous and Ross, 1956; Lees
et al., 1977; Gondim et al., 2010; Friedman et al., 2011; Wand, 2012). This presents challenges
to determining the causes and nature of AH in PD and DLB. The majority of hallucinations in
PD and DLB are chronic, recurring and progressive in spite of stable medication regimens
(Fénelon et al., 2000). Indeed, cognitive, sensory and circadian aspects also contribute to hal-
lucinosis (Mosimann et al., 2006). Neuroleptics are often administered on presentation of AH,
yet have moderate efficacy and potentially severe side effects, including increased mortality
(McKeith et al., 1992a; Weintraub et al., 2016).
Visual hallucinations (VH) constitute a core feature of DLB diagnosis (McKeith et al.,
2017) and have been described as a hallmark of PD (Onofrj et al., 2007). An associated,
but distinct condition, PD dementia (PDD) (Dubois et al., 2007), also presents with motor
and non-motor features, including hallucinations, but is under-reported in the literature. In
PD, PDD and DLB, auditory hallucinations (AH) are generally considered of secondary con-
cern, in spite of the progressive nature of AH, their contribution to loss of insight, decreased
quality of life and consequent influence on the decision to move patients into long-term care
(Goetz and Stebbins, 1993; Aarsland et al., 2000).
Previous reports vary widely in reported prevalence of AH in PD from 2% (Leu-Semenescu
et al., 2011) to 45% (Amar et al., 2014; Llorca et al., 2016). Prevalence rates also range widely in
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DLB, from 18% (Suárez-González et al., 2014) to 43% (Piggott
et al., 2007). Previous studies reporting prevalence of AH have
predominantly been cross-sectional, with limited focus on the
nature of AH reported. Furthermore, methods of determining
the presence of hallucinations are diverse, potentially leading to
differing reporting rates.
Aims of this study: This complex picture suggested a need to
characterise, with increased precision, the prevalence and nature
of AH in PD and DLB. Therefore, in this study, we aimed to con-
duct a systematic review and meta-analysis of studies reporting
AH prevalence in PD and DLB. Furthermore, we aimed to assess
the types of AH in both conditions and compared their preva-
lence with that of VH, which are more commonly investigated.
Methods
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines were used to standardise
the conduct and reporting of this study. The protocol for this
study was registered in advance on PROSPERO (registration
number: CRD42017067337). Ethical approval for this study was
awarded by the Faculty of Science and Engineering Ethics
Committee at Manchester Metropolitan University (EthOS
Reference Number: 0240).
Search strategy
Literature searches for candidate studies were undertaken in the
following databases: PubMed, Web of Science and Scopus.
Search terms were text words: auditory, auditory hallucinations,
hearing, dementia, Lewy bodies, dementia with Lewy bodies,
Lewy body dementia, Parkinson’s disease. The Boolean operator
AND was used to maximise the number of identified papers con-
taining combinations of search terms. A search matrix was used
to ensure all paired combinations of search terms were searched
for in each database.
Study selection
The search was conducted from December 2016 to November
2017. Papers published from 1 January 1970 to 13 November
2017 were considered for inclusion. Titles and abstracts were
examined to remove duplications and irrelevant studies. To be
included, studies needed to (i) be written in English, (ii) report
measures of AH prevalence in patients with PD or DLB, and
(iii) be structured as a prospective cohort, case–control or cross-
sectional study. Unpublished data were not pursued or included.
Both investigators examined full-text versions of studies meeting
the above criteria to assess compliance with inclusion criteria
and extract data. We reviewed reference lists of all included arti-
cles to identify other potentially eligible studies.
Data extraction and risk of bias assessment
Both authors extracted data from included papers, including study
authors; publication year; study title; journal; volume; issue; pages;
study design; number of participants; number of female partici-
pants; number of participants diagnosed with PD/DLB; mean
age of disease onset; number of participants with AH and/or
VH; qualitative descriptions of AH; time window for hallucin-
ation presentation; method of hallucination assessment. Both
reviewers independently evaluated risk of bias for each study
using criteria adapted from the NIH Quality Assessment Tool
for Observational Cohort and Cross-Sectional Studies (https://
www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools).
One point was awarded for each question we felt could be
answered in the affirmative. Our implementation of this tool
assessed study quality across nine domains: aims/objectives stated;
experimental protocol appropriately described; selection bias (see
Results for details); participant inclusion/exclusion criteria
(selected from similar populations/appropriate diagnosis of PD
or DLB); statistical analyses appropriate; condition assessed
prior to outcomes; dropouts reported; timeframe for hallucination
presentation sufficient; outcome measures clearly defined, valid,
reliable and implemented consistently across all study partici-
pants; and presence of detailed qualitative description of AH.
Scores were summed for each study to provide an overall score
of bias and quality. No weighting was used in bias assessment.
Studies were then grouped into those of highest (scores = 9/9),
high (score = 8/9), moderate-to-high (score = 7/9), moderate
(score = 6/9) and poor (score = 1–5/9) quality. Poor quality stud-
ies were excluded (Inzelberg et al., 1998; Katzen et al., 2010; Goetz
et al., 2011; Grau-Rivera et al., 2013). A comparison of all binary
decisions made found 77.4% agreement between the authors.
Discrepancies were settled by discussion and consensus.
Data analysis
Our primary outcome measure was AH prevalence in patients
with PD or DLB. All included studies also reported prevalence
of VH, which we also extracted as a secondary outcome. Where
studies reported longitudinal data, we extracted the maximum
values reported. Prevalence estimates in longitudinal studies
were not higher than other study designs. Indeed, one longitu-
dinal estimate (Goetz et al., 1998) reported the lowest prevalence
of both auditory and VH in PD, suggesting this method did not
bias our findings.
We conducted meta-analyses of AH and VH in Lewy body dis-
ease (LBD; pooled PD and DLB), and PD and DLB. Due to the
range of study designs and different patient populations we antici-
pated would be included in our study, and the consequent assump-
tion that effect sizes would be sampled from a population of effect
sizes that could vary due to factors other than just sampling error,
we planned to carry out random-effects models a priori.
We constructed random-effects models using Comprehensive
Meta-Analyses software (Borenstein et al., 2009). We calculated
pooled prevalence estimates with 95% confidence intervals (CIs)
and assessed heterogeneity using the I2 statistic. Possible publication
bias was assessed via the fail-safe N, Begg’s funnel plot and Begg
and Mazumdar’s rank correlation tests. If publication bias was sus-
pected, we used Duval and Tweedie’s trim and fill to adjust our
prevalence estimates. Outputs from these analyses were imported
to an online forest plot generator to create figures (https://www.evi-
dencepartners.com/resources/forest-plot-generator/).
Meta-regression models were created to investigate the poten-
tial contribution of study-level covariates to the observed hetero-
geneity in our pooled prevalence estimates. Log pooled prevalence
estimate was the dependent variable, while study quality score,
mean age at disease onset and the use of validated methods to
detect hallucinations were set as predictive variables. Due to the
diversity of methods employed to detect hallucinations, it was
not possible to compare each technique. However, a clear distinc-
tion could be drawn between those studies that employed vali-
dated methods [NeuroPsychiatric Inventory (NPI), Manchester
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and Oxford Universities Scale for the Psychopathological
Assessment of Dementia (MOUSPAD), Columbia University
Scale for Psychopathology in Alzheimer’s Disease (CUSPAD),
Psycho-Sensory hAllucinations Scale (PSAS), University of
Miami Parkinson’s Disease Hallucinations Questionnaire (UM-
PDHQ), Parkinson’s Psychosis Rating Scale (PPRS) or Queen
Square Visual Hallucination Inventory (QSVHI)] and those that
did not (Rush Hallucination Inventory, semi-structured interview,
questionnaire, screening hospital records or diagnostic interview
and checklist).
We undertook sensitivity analyses to assess the robustness of
our pooled prevalence estimate of AH and VH. We investigated
the effect of year of publication by sequentially excluding studies
published before 2000, 2005 and 2010. We also examined whether
study design influenced outcomes by examining cross-sectional
studies only and examined the effect of different quality score cut-
off values for inclusion by sequentially excluding studies with
scores of less than seven or eight out of nine.
Results
Study selection
After duplicate removal, we identified 4542 unique articles
through primary database searches. Screening titles and abstracts
led to the elimination of 4499 irrelevant articles. Full-text versions
of the remaining 43 potentially eligible articles were assessed. Of
these, 13 did not meet inclusion criteria, leaving 30 articles, pub-
lished between 1992 and 2016, in the qualitative synthesis. A fur-
ther four articles were excluded from quantitative meta-analyses
due to low-quality assessment scores (Fig. 1). This produced 26
studies eligible for inclusion in the meta-analysis of AH preva-
lence (online Supplementary Table S1).
Characteristics of included studies
Of the included studies, 19 were cross-sectional studies, four were
longitudinal studies and three were case–control studies. These
studies represent data from 10 countries, the majority of which
were conducted in Europe (n = 15), while others were undertaken
in North America (n = 6) and Asia (n = 5).
Five studies (Ballard et al., 1999; Aarsland et al., 2000; Ballard
et al., 2001; Piggott et al., 2007; Williams et al., 2008) diagnosed
DLB using McKeith et al. (1996) consensus criteria, two
(Suárez-González et al., 2014; Shea et al., 2015) employed the
McKeith (2006) consensus criteria, while one (Klatka et al.,
1996) used post-mortem neuropathologic diagnosis.
Fifteen studies (Fernandez et al., 1992; Graham et al., 1997;
Fénelon et al., 2000; Holroyd et al., 2001; Gupta et al., 2004; de
Maindreville et al., 2005; Pacchetti et al., 2005; Papapetropoulos
et al., 2008; Williams et al., 2008; Fénelon et al., 2010; Mack
et al., 2012; Svetel et al., 2012; Amar et al., 2014; de Chazeron
et al., 2015; Llorca et al., 2016) diagnosed PD according to a ver-
sion of the United Kingdom Parkinson’s Disease Society Brain
Bank Criteria (Gibb and Lees, 1988). Five other studies used dif-
ferent diagnostic criteria, including definite or probable PD based
on Larsen et al. (1994) criteria (Aarsland et al., 2000); Calne et al.
(1992) criteria (Paleacu et al., 2005); Gelb et al. (1999) criteria
(Lee and Weintraub, 2012); Core Assessment Program for
Intracerebral Transplantations; Langston et al. (1992) criteria
(Goetz et al., 1998); or criteria of Hughes et al. (1992) for idio-
pathic PD (Leu-Semenescu et al., 2011).
Our quality assessment rated four studies as highest quality
(score = 9/9), 12 as high quality (8/9), seven as moderate-to-high
quality (7/9) and four as moderate quality (6/9) (online
Supplementary Table S2). As a population, study quality was
weakest in reporting of qualitative descriptions of hallucinations,
with other areas of quality assessment scoring being consistently
high among included studies.
Demographics of dataset
The mean age at onset of diagnosis was 61.9 years (S.D. = 7.6). We
attempted to conduct group wise comparisons between diagnoses
of PD without dementia (PDWD), PDD and DLB; however, PDD
and PDWDwere only separately reported in one study; consequently,
these data were pooled into one PD group. Data from 3774 patients
were identified, of which 3420 (90.6%) had PD, with the remainder
DLB, and 1178 (31.2%) were female (range = 3.3–60.4%). A higher
proportion of females were found in the DLB group (mean =
48.6%; range = 20.0–56.1%), than PD (mean = 30.6%; range = 3.3–
60.4%). Mean age at onset for DLB was 74.1 years (S.D. = 8.1), while
mean age at onset for PD was 58.8 years (S.D. = 10.6).
Overall pooled prevalence of AH
The overall random-effects model pooled prevalence of AH in LBD
(Fig. 2) was 11.9% (95% CI ±7.9 to 17.7). To compare the relative
prevalence of AH in DLB and PD, two further random-effects
models were constructed for each condition, independent of the
other. Pooled prevalence of AH in DLB (Fig. 3a) was 30.8%
(±23.4 to 39.3), while in PD (Fig. 3b), it was 8.9% (±5.3 to 14.5).
Overall pooled prevalence of VH
We also extracted information on VH from the 26 included stud-
ies. The study by Leu-Semenescu et al. (2011) reported selection
bias for this analysis as all 100 PD patients had VH due to the
study design, and was therefore excluded leaving 25 studies in
this analysis. The overall random-effects pooled prevalence of
VH in LBD (Fig. 4) was 35.9% (±26.2 to 47.0). Pooled prevalence
of VH in DLB (Fig. 5a) was 61.8% (±49.1 to 73.0), while in PD
(Fig. 5b), it was 28.2% (±19.1 to 39.5).
Low prevalence of single modality auditory or VH
Pure sensory hallucinations (i.e. those in only one single sensory
domain) were less common. There were two (0.6%) reports of
pure AH in DLB and 23 (0.7%) in PD. Pure VH were more com-
mon than auditory in both conditions, being found in 36 (10.2%)
DLB cases and 122 (3.6%) PD cases. Qualitative analysis of included
longitudinal studies (Graham et al., 1997; Goetz et al., 1998; Ballard
et al., 2001; de Maindreville et al., 2005) revealed that pure VH
tended to predate AH in both PD and DLB. As each condition pro-
gressed, AH tended to bind with recurrent complex VH to form
multi-modal hallucinations that increased in prevalence from 1.5
to 10 years post baseline assessment (Goetz et al., 2011).
Types of AH
The rate of reporting qualitative descriptions of AH was low, with
data only available from six studies; five of which described data
from PD patients, while the other described data from DLB
patients.
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The most commonly reported type of AH were verbal, which
were reported in all six studies. Verbal AH were reported as
human voices originating from outside the patient’s head, often
indistinct or incomprehensible, originating outside the visual
field. Verbal AH were described as ‘non-threatening’, ‘non-
imperative’, ‘non-congruent’ and ‘non-paranoid’. Three studies
reported the proportion of AH that were verbal: Amar et al.
(2014) found 11/18 (61.1%) of patents had verbal AH in PD;
Fénelon et al. (2000) reported a similar proportion in PD – 13/
21 (61.9%); while Suárez-González et al. (2014) found 5/14
(35.7%) had verbal AH in DLB.
Non-verbal sounds, such as inanimate (bullet fired, doorbell
ringing, tinkling of bells, walking on steps, cracking sounds or
squeaking) or animate sounds (dogs barking, tigers and lions
roaring) were also common. Musical hallucinations were rare,
being reported in only three patients by Fénelon et al. (2000),
two of whom were described as ‘deaf’.
Hallucination assessment
Across the 26 studies, there were 10 different methods employed
to determine the presence of hallucinations (online
Supplementary Table S1). The most common method was a semi-
structured interview (n = 10), followed by NPI (n = 5), CUSPAD
(n = 2), PSAS (n = 2), unnamed questionnaire (n = 2), UM-
PDHQ (n = 1), MOUSPAD (n = 1), PPRS (n = 1), QSVHI (n = 1),
screening of hospital records (n = 1) and not stated (=1).
Meta-regression analyses
We observed considerable heterogeneity in all meta-analyses (I2
range = 51.2–96.3), suggesting a large proportion of the observed
variance may be due to real differences between studies. To inves-
tigate whether some of the observed heterogeneity could be
explained by moderator variables, such as study quality score,
mean age of disease onset or method of hallucination assessment,
we constructed meta-regression models for those meta-analyses
comprised of sufficient study numbers (LBD and PD but not
DLB). The results of these four models (online Supplementary
Table S3) revealed the use of validated hallucination assessment
methods could explain a significant proportion of the variance
for each meta-regression (R2 range = 0.09–0.38), but study quality,
mean age at disease onset and disease duration could not.
The fail-safe N for our meta-analysis of AH in LBD was 5649
(Z =−28.9; p < 0.0001), while there was only minor asymmetry in
Begg’s funnel plot (online Supplementary Fig. S6A). Begg and
Mazumdar’s rank correlation test suggested that publication bias
was not present (Kendall’s Τ-b =−0.23; p = 0.09) and employing
Duval and Tweedie’s trim and fill did not modify the
random-effects effect size estimate. Similar values were found
Fig. 1. PRISMA flow diagram demonstrating study selection process.
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for our meta-analyses of AH in PD (online Supplementary
Fig. S6B) and DLB (online Supplementary Fig. S6C), though
trim and fill on the latter analysis imputed three studies that
increased the pooled prevalence estimate to 37.5% (±27.7 to 48.5).
The fail-safe N for our meta-analysis of VHs in LBD was
1280 (Z =−14.16; p < 0.0001), while there was only minor asym-
metry in Begg’s funnel plot (online Supplementary Fig. S6D).
Begg and Mazumdar’s rank correlation test suggested that
publication bias was not present (Kendall’s Τ-b = −0.11;
p = 0.44) and employing Duval and Tweedie’s trim and fill did
not modify the random-effects estimate. Similar values were
found for our meta-analyses of VH in PD (online
Supplementary Fig. S6E) and DLB (online Supplementary
Fig. S6F), though trim and fill on the former analysis imputed
four studies and increased the pooled prevalence estimate to
33.4% (±31.4 to 35.4).
We further investigated the potential role of cognition in hallu-
cination status. Mini-Mental State Examination (MMSE) scores
Fig. 2. Forest plot showing random-effects model estimate of AH overall pooled prevalence of 11.9% (±7.9 to 17.7) in Lewy body disease (LBD = DLB, PDD and PDND
combined). I2 = between-study heterogeneity; POP = study population; PREV = prevalence; LCL = lower confidence level; UCL = upper confidence level; WGHT =
weight under random effects model.
Psychological Medicine 5
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Fig. 3. Forest plot showing random-effects model estimates of AH prevalence of 30.8% (±23.4 to 39.3) in DLB and 8.9% (±5.3 to 14.5) in PD.
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were reported in 16 studies (10 PD cases only; four DLB only; two
both conditions). Pooled MMSE scores ranged from 13.2 to 29.2
(mean = 24.1). For PD, MMSE scores were lower (mean = 25.9;
S.D.± = 2.3) for cases with hallucinations than those without
(27.6 ± 1.2). For DLB, MMSE scores were similar for cases with
hallucinations (17.3 ± 3.0) and those without hallucinations
(17.2 ± 3.1). A correlation analysis found a negative relationship
between MMSE scores and AH prevalence [r(s) =−0.61; p = 0.008].
Sensitivity analyses
We assessed the impact of year of study, study design and quality
score on the robustness of our pooled prevalence estimates of
auditory and VH in LBD. These analyses indicated that our esti-
mates were robust, but were a few percentage points lower than
analyses only including studies published from 2010 onwards or
analyses only including moderate-to-high and high-quality stud-
ies (online Supplementary Table S4).
Discussion
We report that AH and VH present in a significant proportion of
PD and DLB cases, with both forms of hallucination being more
prevalent in DLB. We found that VH have a higher prevalence
than AH in both conditions, both occurring at rates much higher
than those found in the general population (Ohayon, 2000;
Fig. 4. Forest plot showing random-effects model estimate of VH prevalence of 35.9% (±26.2 to 47.0) in LBD.
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Fig. 5. Forest plot showing random-effects model estimates of VH prevalence of 61.8% (±49.1 to 73.0) in DLB and 28.2% (±19.1 to 39.5) in PD.
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Waters et al., 2018). Of note were the wide variety of methods
used to determine the presence of hallucinations. We found
that more recently published studies, using validated methods,
produced higher estimates of hallucination prevalence, suggesting
a need for wider adoption of such approaches. Taken together,
these data demonstrate that AH have a higher prevalence in PD
and DLB than commonly assumed.
Challenges to existing models of hallucinations
Existing models of recurrent complex VH have considered VH to
exist in isolation from other modalities. Some models highlight
dysfunctional attentional, cognitive and perceptual networks
(Collerton et al., 2005; Diederich et al., 2005; Shine et al.,
2011). Our data suggest that in PD and DLB, most cases of VH
progress to become multi-modal hallucinations, incorporating a
bound AH to the VH (e.g. hallucinations of people progress
such that they can be heard talking). Attentional-cognitive models
could account for these observations; however, sensory deficits
seem incongruous with bottom-up perceptual elements of existing
models. The contribution of bottom-up sensory aspects to VH
has been shown via studies detailing ocular (Urwyler et al.,
2014) and occipital lobe dysfunction (Meppelink et al., 2009),
while central, top-down contributions involving frontal
(Sanchez‐Castaneda et al., 2010) and temporal (Harding et al.,
2002) lobes also play a role.
However, hearing loss and auditory dysfunction are common at
ages associated with PD and DLB diagnosis (Lin et al., 2011). It is
therefore challenging to account for VH progressing to multi-
modal hallucinations, binding with AH, due to a visual perceptual
deficit occurring in these cases, followed by an auditory deficit.
Models of simple AH, such as tinnitus, incorporate loss of periph-
eral drive with adaptive changes in gain (Eggermont, 1990), reduc-
tions in inhibition throughout the auditory pathway (Wang et al.,
2011) and mismatches with central predictive coding (Sedley
et al., 2016), yet rarely do these changes lead to more complex AH.
Attentional networks may tend to be directed more towards
the visual scene, leading to more prevalent reporting of VH
when these networks dysfunction. This may be due to attentional
focus being more easily directed towards visual than auditory
objects (Shinn-Cunningham, 2008). As widespread degeneration
progresses, attentional deficits may facilitate widespread connect-
ivity and phantom binding of VH with AH, perhaps acting via
hyperexcitable cortical and subcortical networks (Grossberg,
2000; Robson et al., 2018).
Strengths and limitations
Our findings are supported by the large proportion of moderate-
to-high quality studies included in our meta-analyses (online
Supplementary Table S2). The accuracy of our prevalence estimates
are supported by the majority of studies being cross-sectional, the
best experimental design by which to estimate prevalence (Mann,
2003). Furthermore, our sensitivity analyses showed that only
including cross-sectional studies had little effect on our estimates
(online Supplementary Table S4). However, the time window for
detection of auditory or VH ranged up to 30 years post-diagnosis
(Graham et al., 1997), limiting the temporal precision of our esti-
mates. A selection bias may exist in our estimates due to studies
selecting patients from movement disorder clinics with few
community-based samples; future studies of different populations
may allow insights into hallucinations in different populations.
The use of various methods to identify hallucinations was a
major contributor to the high degree of heterogeneity in our
meta-analyses (online Supplementary Table S3). Meta-regression
models found that validated methods produced higher prevalence
estimates than non-validated, suggesting that there are advantages
to such approaches. However, within the range of validated
measures reported in our sample (UM-PDHQ, MOUSPAD,
CUSPAD, PSAS, PPRS, NPI and QSVHI) exist substantial differ-
ences in approach and outcomes. Comparisons between these
approaches are beyond the scope of this study. Future work com-
paring these methods within the same study population may be
useful. Method of hallucination assessment is an important
issue, as most patients do not report AH when they first perceive
them (Chou et al., 2005). This may be due to AH being less easily
identified than visual, but could also be due to patient knowledge
that AH are commonly associated with psychiatric conditions.
Our initial focus was to estimate AH prevalence in PD and
DLB. As all studies included in this analysis also reported the
number of participants who had VH, we also extracted and ana-
lysed these data. Numerous papers in the literature report VH but
do not report other forms of hallucinations. Consequently, our
estimates of VH do not contain all available evidence, but do pro-
vide comparison data that allow us to have confidence that VH
are more common than AH.
Across the timespan of included studies, diagnostic criteria for
PD have largely remained unchanged; while there have been mul-
tiple iterations of the consensus criteria for DLB diagnosis, each of
which has modified the specificity and sensitivity of this diagnosis
(Rizzo et al., 2017). This may be another source of between-
studies heterogeneity; however, the low number of DLB studies
included in our analyses did not allow meta-regression models
to be constructed for these data. The lowest I2 values we observed
in our meta-analyses were found for DLB studies (Figs 3a and 5a),
which argues against the possible contribution of diagnostic cri-
teria to the observed heterogeneity.
Two potentially confounding covariates were later age of diagno-
sis of DLB than PD and the inclusion of lower quality studies (online
Supplementary Table S2). Importantly, neither of thesewas found to
account for a significant proportion of the variance in our
meta-regression models (online Supplementary Table S3). This
does not exclude the possibility that age of diagnosis or age per se
contributes to hallucinosis. Indeed, the presentation of VH in age-
matched DLB and PDDpatients shows extensive overlap, suggesting
age-related changes may contribute to their generation (Mosimann
et al., 2006). We were able to include data from four longitudinal
cohort studies; however, two of these studies reported data for
1-year post-diagnosis, meaning that estimates of point prevalence
over time were not possible in the present study. There is evidence
that hallucination point prevalence in PD increases over time to
affect a majority of patients (Goetz et al., 2005; Hely et al., 2008).
Indeed, there is evidence that hallucinations increase in prevalence
with age, post-PD diagnosis (Graham et al., 1997; Biglan et al.,
2007), with VH progressing towards polysensory phenotypes
(Goetz et al., 2011). Furthermore, once perceived, hallucinations
generally recur and are accompanied by a lack of insight (Goetz
et al., 2006), leading to increased risk of requiring placement in
care facilities (Goetz and Stebbins, 1993; Aarsland et al., 2000).
Types of AH
AH in LDB are complex, typically polymodal and varied in their
presentation, although there is a paucity of high-quality,
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qualitative descriptions. Most common were verbal AH, perceived
as originating outside the head, which differentiates verbal AH in
PD or DLB from those found in schizophrenia. Interestingly, of
the three studies to report relative rates of different types of
AHs, two found that verbal hallucinations formed the majority
in PD (Fénelon et al., 2000; Amar et al., 2014) while
Suárez-González et al. (2014) reported that these were a minority
in DLB. This may suggest a difference in AH presentation
between the two conditions.
Non-verbal AH (acouasms) were also common and complex,
whether animate or inanimate. These findings suggest auditory
cortex and wider temporal and frontal lobe involvement in AH
in PD and DLB, a speculation that is supported by neuroimaging
data (Matsui et al., 2006). Some reports of simpler acouasms were
also reported. The potential overlap between acouasms and tin-
nitus suggests that our estimated pooled prevalence of AH may
be lower than the true prevalence in the population. Indeed, a
recent cross-sectional study found that in a sample of 1000
patients in a cognitive neurology clinic, verbal and musical hallu-
cinations had a prevalence of 0.9%, while tinnitus was present in
6.9% (Bayón et al., 2017).
AH were described as providing a soundtrack to VH (Fénelon
et al., 2000), such as when a patient hears conversations of visu-
ally hallucinated people talking. This presentation is of note, as
numerous authors described VH as preceding AH, while the poly-
modal combination of VH and AH may provide diagnostic utility
in differentiating cognitive and functional impairment in DLB
from Alzheimer’s disease (Suárez-González et al., 2014). These
data agree with early operation criteria for DLB diagnosis
(McKeith et al., 1992b). While the first consensus guidelines for
DLB diagnosis included AH as supportive features (McKeith
et al., 1996), more recent updates have removed them from con-
sideration (McKeith, 2006; McKeith et al., 2017). A recent ana-
lysis found that the consensus criteria for DLB had become
more sensitive but less specific through these iterations, with little
change in diagnostic accuracy (Rizzo et al., 2017). Whether the
use of validated methods to detect AH is of any diagnostic utility
in DLB or PD requires further investigation.
It is interesting to note that two of the three participants who
reported musical hallucinations in our sample were described as
‘deaf’ (Fénelon et al., 2000). Musical hallucinations have been
associated primarily with hearing impairment (Gordon, 1997;
Cope and Baguley, 2009; Perez et al., 2017), though they have
been reported in PD (Ergün et al., 2009) and DLB (Golden and
Josephs, 2015) without hearing impairment. The contributions
and potential interactions between hearing impairment and PD
or DLB require further investigation, as there are suggestions
that hearing impairment may present as a non-motor feature of
PD (Lai et al., 2014) and hearing impairment may be more com-
mon in PD than age-matched controls (Yýlmaz et al., 2009).
Conclusion
This study is the first, to our knowledge, to summarise, synthesise
and contrast evidence for AH and VH prevalence in PD and DLB.
AH and VH contribute to disease burden in a significant propor-
tion of LDB cases. Methods of identification and assessment of
AH and VH requires investigation to standardise measurements.
Successful developments in this field may improve the accuracy of
hallucination diagnosis and inform disease progression monitor-
ing and interventions.
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